Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Aslan Pharma of Singapore Raises $12 Million for In-licensing

publication date: Apr 27, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Aslan Pharmaceuticals Pte. Ltd. of Singapore announced a $12 million Series A funding, which it will use to in-license novel medicines. The company’s business model is to partner development-stage drugs that are 6-12 months from entering the clinic, perform Phase I and II studies in Asia to obtain Proof of Concept, and then out-license the compounds back to partners for global development. More details....

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners